News
NTRB
6.70
+0.30%
0.02
Weekly Report: what happened at NTRB last week (0928-1002)?
Weekly Report · 2d ago
Nutriband Marks Five Years on Nasdaq – CEO Letter to Shareholders
Barchart · 6d ago
Press Release: Nutriband CEO Gareth Sheridan Featured in New Nick Shirley Documentary Confronting America's Opioid Crisis
Dow Jones · 09/29 13:25
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 09/28 12:05
Weekly Report: what happened at NTRB last week (0921-0925)?
Weekly Report · 09/28 10:25
Why Webuy Global Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Benzinga · 09/28 09:29
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 09/25 17:05
Nutriband appoints O’Neill to Advisory Board
TipRanks · 09/25 12:15
Nutriband Appoints Decorated Navy SEAL and Veterans Health Advocate Robert J. O'Neill to Advisory Board
Barchart · 09/25 07:00
Weekly Report: what happened at NTRB last week (0914-0918)?
Weekly Report · 09/21 10:25
Weekly Report: what happened at NTRB last week (0907-0911)?
Weekly Report · 09/14 10:31
Nutriband CEO, Gareth Sheridan to Attend the Nasdaq Life Sciences Advisory Board (LaB) Biotech Summit
Barchart · 09/09 08:20
Nutriband receives notice of publication from USPTO
TipRanks · 09/08 13:26
Weekly Report: what happened at NTRB last week (0831-0904)?
Weekly Report · 09/07 10:24
Nutriband Q2 EPS $(0.07) Up From $(2.12) YoY, Sales $437.514K Down From $622.452K YoY
Benzinga · 09/04 21:46
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 09/03 17:06
Weekly Report: what happened at NTRB last week (0824-0828)?
Weekly Report · 08/31 10:32
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 08/24 17:06
Weekly Report: what happened at NTRB last week (0817-0821)?
Weekly Report · 08/24 10:33
Weekly Report: what happened at NTRB last week (0810-0814)?
Weekly Report · 08/17 10:34
More
Webull provides a variety of real-time NTRB stock news. You can receive the latest news about Nutriband Inc through multiple platforms. This information may help you make smarter investment decisions.
About NTRB
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.